Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Operating Expenses (2022 - 2025)

Summit Therapeutics' Operating Expenses history spans 4 years, with the latest figure at $224.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 242.8% year-over-year to $224.9 million; the TTM value through Dec 2025 reached $1.1 billion, up 384.26%, while the annual FY2025 figure was $1.1 billion, 384.26% up from the prior year.
  • Operating Expenses reached $224.9 million in Q4 2025 per SMMT's latest filing, down from $234.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $568.4 million in Q2 2025 to a low of $15.8 million in Q2 2023.
  • Average Operating Expenses over 4 years is $141.0 million, with a median of $59.0 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: tumbled 92.12% in 2024, then soared 853.48% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $21.4 million in 2022, then surged by 65.12% to $35.4 million in 2023, then surged by 85.41% to $65.6 million in 2024, then surged by 242.8% to $224.9 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Operating Expenses are $224.9 million (Q4 2025), $234.2 million (Q3 2025), and $568.4 million (Q2 2025).